In the third instalment of our Medical Monitoring Masterclass to celebrate Clinical Trials Day 2026, we’re looking at clinical risk and what quality oversight means for your asset.

What Investors Need to Know About Clinical Risk

Investing in a clinical-stage biotech or pharmaceutical asset is an exercise in risk assessment. Every investor – whether a venture fund, a family office, or a strategic pharma partner – is asking the same fundamental question: how confident can I be that this asset will deliver what it promises?

Scientific hypothesis and mechanism of action are important. But the quality of the clinical evidence that supports the asset is equally critical. And the quality of that evidence is directly shaped by how well the clinical trial was designed, conducted, and monitored.

Medical Monitoring as a Risk Mitigation Tool

Medical monitoring is, at its core, a risk management activity. It is the process by which qualified physicians and scientists systematically review clinical trial data – participant by participant, site by site – to ensure that safety signals are identified early, that data integrity is maintained, and that the trial is being conducted in accordance with the protocol and applicable regulations.

When medical monitoring is done well, it protects the asset in several important ways:

• Safety signals are detected early, enabling timely decisions that prevent participant harm and avoid the regulatory consequences of late detection;
• Data quality is maintained throughout the trial, reducing the risk of queries or requests for additional information during regulatory review;
• Protocol deviations are identified and addressed before they accumulate into a pattern that could undermine the validity of the dataset;
• The sponsor can demonstrate to regulators and to investors that the programme has been run with rigorous oversight.

The ICH E6(R3) Signal

The arrival of the updated ICH E6(R3) guidelines in 2025 is a signal that the regulatory environment is moving firmly in the direction of risk-based, quality-by-design oversight. Programmes that are designed and monitored in accordance with these principles will be better positioned for regulatory success and will carry lower risk for investors.

Conversely, programmes that have not engaged expert medical monitoring, or that have treated it as a peripheral activity, may find themselves exposed when regulators ask detailed questions about how safety data was reviewed, how adverse events were managed, and how data integrity was assured throughout the trial.

What to Look For in Due Diligence

When conducting due diligence on a clinical-stage asset, in addition to verifying the scientific data, investors and their advisors should consider asking:

• Who is providing medical monitoring for this programme, and what are their qualifications?
• How is the medical monitor integrated into the clinical team, and at what stage were they engaged?
• What is the adverse event review frequency, and how are safety signals escalated?
• Is the monitoring plan compliant with ICH E6(R3) quality by design principles?

These questions are not generally included in due diligence but are critical indicators of whether a programme is run with the expertise and discipline that gives clinical data its credibility.

Pharmora: Expert Medical Monitoring for Investor-Ready Programmes

At Pharmora, we work with biotechs to build clinical programmes that are not only scientifically rigorous but demonstrably well-run. Our medical monitoring services provide the systematic, expert oversight that gives sponsors and their investors confidence in the quality of the data being generated.

Whether you are preparing for a funding round, a licensing discussion, or a regulatory submission, the question of how your trial was monitored will be asked. Pharmora ensures you can answer it with confidence.

In case you missed a previous instalment, or are looking to read the rest of this exciting masterclass, click the links below to navigate through the series:
1 – What is it and why does it matter?
2 – Medical Monitoring for Biotechs
4 – Medical Monitoring in Biosimilar Development
5 –  Medical Monitoring in Generics Development

To find out how Pharmora can support your programme, contact us at info@pharmora.com or visit www.pharmora.com.